According to results of a study long-term use of romidepsin in a dose-sparing regimen to treat cutaneous T-cell lymphoma may be a useful strategy to try to prolong disease response.
Home / Resource Library / Durable Responses With Maintenance Dose-Sparing Regimens of Romidepsin in Cutaneous T-Cell Lymphoma